



Marco de Morpurgo

Socio

GLOBAL CO-CHAIR, LIFE SCIENCES SECTOR

marco.demorpurgo@dlapiper.com

Roma

T: +39 06 68 880 1

F: +39 06 68 880 201

Marco de Morpurgo focuses on government regulation of the Life Sciences industry. He helps companies doing business in the EU navigate the complex regulatory structures governing the sector, counseling such clients on regulatory strategies and compliance matters.

His practice covers the regulation of pharmaceuticals, biotechnologies, medical devices, and other health-related regulated products in the EU. He provides strategic advice on a broad range of regulatory issues, including clinical trials, product approvals, market access, promotion and advertising, post-market obligations, as well as on industry-specific ethical and behavioral rules. Most of Marco's work is multi-jurisdictional and he has broad experience assisting clients manage regulatory divergence within the EU and globally.

He regularly speaks and writes on Life Sciences topics. He is a member of the Editorial Board of the European Pharmaceutical Law Review and teaches Life Sciences Law at HEC Paris.

- Intellectual Property and Technology

- Biotecnología

Italiano Inglés Francés
Español

IDIOMAS

- Italiano
- Inglés
- Francés
- Español

Cualificaciones profesionales

- Avvocato admitted to the Rome Bar
- Avocat admitted to the Paris Bar
- Abogado del Ilustre Colegio de Abogados de Madrid

- Attorney-at-law admitted with the Supreme Court of New York

Experiencia previa

- Before joining DLA Piper, Marco worked with leading international law firms in Brussels, London and Paris.

Formación

- University of Milan, Ph.D., Comparative Law
- Harvard Law School, LL.M.
- IUC Turin, M.Sc., Comparative Law, Economics & Finance
- University of Trieste, Law degree

NOVEDADES

Publicaciones

Embracing Digital Evolution: Our new business report

14 September 2021

Our new report - *Embracing Digital Evolution* - shows how businesses can succeed in Industry 4.0, with contributions from digital revolutionaries such as Microsoft, Salesforce, Rolls-Royce and DocuSign.

Digital Therapeutics - evolution and entry into mainstream healthcare

18 September 2020

Research undertaken by DLA Piper's Life Sciences sector in conjunction with The Lawyer seeks to understand the current developments in the field of digital therapeutics, looking at key questions that need to be addressed if these products are to become mainstream components of health systems across the world.

Clinical trials during the COVID-19 pandemic: A global guide

2 July 2020

The consequences of the COVID-19 pandemic continue to develop dynamically. Some countries are beginning to ease lockdown measures, whilst others retain or even impose new restrictions. The situation continues to impact the ability to conduct clinical trials on a global scale. Pharmaceutical companies need to address even more challenges to ensure the continuity of trials on human medicines.

Clinical trials during the COVID-19 pandemic: A global guide

17 April 2020

The unprecedented situation resulting from the COVID-19 pandemic impacts the ability to conduct clinical trials on a global scale. Pharmaceutical companies need to address multiple challenges to ensure the continuity of trials on human medicines.

European Commission proposes one-year postponement of MDR application date

8 April 2020

Following an informal heads-up on 25 March 2020, today the European Commission adopted a proposed regulation to postpone by one

year the date of application of the Medical Devices Regulation (Regulation (EU) 2017/745, "MDR"). If enacted, the Medical Device Directive (Directive 93/42/EEC) and implementing legislation of the EU member states will continue to apply as far as they have not yet been amended.

Italian Medicines Agency tackles challenges related to clinical trial management during COVID-19 emergency

20 March 2020

In the recent UK Budget, and subsequent announcements, several initiatives have been introduced to support businesses in response to coronavirus COVID-19, but as yet there are no generally applicable leniencies on when tax has to be paid or returns filed. Read to find out more.

Italian DLA Piper Intellectual Property & Technology Legal Predictions for 2020

28 February 2020

DLA Piper Italian Intellectual Property & Technology practice group has published its Legal Predictions for 2019. These take a look back at what happened during 2019 and illustrate the key changes that are expected in 2020.

- EU SPC Manufacturing Waiver Becomes Effective: What Can Industry Expect?, European Pharmaceutical Law Review, Volume 3, Issue 3 (2019)
- The Sun Also Rises in Italy: New Statutory Transparency Requirements Expected under the Proposed Italian Sunshine Act, European Pharmaceutical Law Review, Volume 2, Issue 4 (2018)
- Italy Reforms Clinical Trial Rules, European Pharmaceutical Law Review, Volume 2, Issue 1 (2018)

NOTICIAS

DLA Piper launches global cannabis practice

21 February 2020

DLA Piper has launched a dedicated global cannabis practice that will sit as a sub-group under its Life Sciences sector. The decision to formalise the firm's offering follows the completion of a significant number of global deals in the sector that have amounted to over USD8 billion to date, as well as a number of large cannabis regulatory advisory mandates.
